JP2019512216A5 - - Google Patents

Info

Publication number

JP2019512216A5

JP2019512216A5 JP2018544213A JP2018544213A JP2019512216A5 JP 2019512216 A5 JP2019512216 A5 JP 2019512216A5 JP 2018544213 A JP2018544213 A JP 2018544213A JP 2018544213 A JP2018544213 A JP 2018544213A JP 2019512216 A5 JP2019512216 A5 JP 2019512216A5

Authority

JP

Japan

Prior art keywords

functional fragment

polypeptide

calcium channel

inhibiting

orai1

Prior art date

2017-02-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims 46
• 229920001184 polypeptide Polymers 0.000 claims 33
• 102000004196 processed proteins & peptides Human genes 0.000 claims 33
• 108090000765 processed proteins & peptides Proteins 0.000 claims 33
• 108090000312 Calcium Channels Proteins 0.000 claims 22
• 102000003922 Calcium Channels Human genes 0.000 claims 22
• 238000000034 method Methods 0.000 claims 16
• 230000002401 inhibitory effect Effects 0.000 claims 12
• 101150060735 orai1 gene Proteins 0.000 claims 11
• 210000004027 cell Anatomy 0.000 claims 7
• 125000000539 amino acid group Chemical group 0.000 claims 5
• 230000009460 calcium influx Effects 0.000 claims 5
• 102000040430 polynucleotide Human genes 0.000 claims 5
• 108091033319 polynucleotide Proteins 0.000 claims 5
• 239000002157 polynucleotide Substances 0.000 claims 5
• 101000899089 Homo sapiens BPI fold-containing family A member 1 Proteins 0.000 claims 4
• 125000003275 alpha amino acid group Chemical group 0.000 claims 4
• 230000004071 biological effect Effects 0.000 claims 4
• 210000004899 c-terminal region Anatomy 0.000 claims 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
• 102000051040 human BPIFA1 Human genes 0.000 claims 4
• 208000023275 Autoimmune disease Diseases 0.000 claims 3
• 208000035475 disorder Diseases 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 206010061218 Inflammation Diseases 0.000 claims 2
• 241001465754 Metazoa Species 0.000 claims 2
• 230000036428 airway hyperreactivity Effects 0.000 claims 2
• 210000005091 airway smooth muscle Anatomy 0.000 claims 2
• 150000001413 amino acids Chemical class 0.000 claims 2
• 230000028993 immune response Effects 0.000 claims 2
• 230000004054 inflammatory process Effects 0.000 claims 2
• 230000016160 smooth muscle contraction Effects 0.000 claims 2
• 206010020751 Hypersensitivity Diseases 0.000 claims 1
• 208000026935 allergic disease Diseases 0.000 claims 1
• 230000007815 allergy Effects 0.000 claims 1
• 208000006673 asthma Diseases 0.000 claims 1
• 238000004113 cell culture Methods 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 238000000338 in vitro Methods 0.000 claims 1
• 230000005764 inhibitory process Effects 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1